Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Ordinary Shares, NIS 1.80 par value per share
-
Shares outstanding
-
5,591,387
-
Total 13F shares
-
75,987
-
Share change
-
+20,111
-
Total reported value
-
$140,174
-
Price per share
-
$1.86
-
Number of holders
-
14
-
Value change
-
+$46,243
-
Number of buys
-
7
-
Number of sells
-
3
Institutional Holders of Galmed Pharmaceuticals Ltd. - Ordinary Shares, NIS 1.80 par value per share (GLMD) as of Q2 2025
As of 30 Jun 2025,
Galmed Pharmaceuticals Ltd. - Ordinary Shares, NIS 1.80 par value per share (GLMD) was held by
14 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
75,987 shares.
The largest 10 holders included
MORGAN STANLEY, Schonfeld Strategic Advisors LLC, Cambridge Investment Research Advisors, Inc., UBS Group AG, SBI Securities Co., Ltd., Physician Wealth Advisors, Inc., Federation des caisses Desjardins du Quebec, RAYMOND JAMES FINANCIAL INC, WELLS FARGO & COMPANY/MN, and OSAIC HOLDINGS, INC..
This page lists
14
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.